Neurology Research
Epilepsy
Key Facts
About Renovaro BioSciences
Renovaro BioSciences, founded in 2013 and based in Los Angeles, is developing an AI-driven biology platform under the Lunai Bioworks banner to transform drug discovery. The company integrates genomic, proteomic, and phenotypic data with high-throughput in vivo modeling to uncover disease mechanisms and therapeutic candidates with higher precision. It is advancing internal programs in oncology and neurology while also pursuing strategic partnerships with pharmaceutical companies. Renovaro is a public company, positioning itself at the intersection of AI and biologics to address complex diseases.
View full company profileAbout Renovaro BioSciences
Renovaro BioSciences, founded in 2013 and based in Los Angeles, is developing an AI-driven biology platform under the Lunai Bioworks banner to transform drug discovery. The company integrates genomic, proteomic, and phenotypic data with high-throughput in vivo modeling to uncover disease mechanisms and therapeutic candidates with higher precision. It is advancing internal programs in oncology and neurology while also pursuing strategic partnerships with pharmaceutical companies. Renovaro is a public company, positioning itself at the intersection of AI and biologics to address complex diseases.
View full company profileAbout Renovaro BioSciences
Renovaro BioSciences, founded in 2013 and based in Los Angeles, is developing an AI-driven biology platform under the Lunai Bioworks banner to transform drug discovery. The company integrates genomic, proteomic, and phenotypic data with high-throughput in vivo modeling to uncover disease mechanisms and therapeutic candidates with higher precision. It is advancing internal programs in oncology and neurology while also pursuing strategic partnerships with pharmaceutical companies. Renovaro is a public company, positioning itself at the intersection of AI and biologics to address complex diseases.
View full company profileTherapeutic Areas
Other Epilepsy Drugs
| Drug | Company | Phase |
|---|---|---|
| ADX71149 (mGlu2 PAM) | Addex Therapeutics | Phase 2 |
| TRV045 | Trevena | Phase 1 |
| SAGE-324 | Sage Therapeutics | Preclinical |
| Motpoly XR™ | Aucta Pharmaceuticals | Not Specified (Likely Phase 3/NDA) |
| ADB-104 | Adolore BioTherapeutics | Pre-clinical |
| Not Publicly Disclosed | Cerecin | Phase 2 |
| eTNS Platform | NeuroSigma | Unknown |
| NPT 2042 | NeuroPro Therapeutics | Phase 2 |
| Spritam (levetiracetam) | Aprecia Pharmaceuticals | Approved |
| Perampanel | Ark Diagnostics | In Development |
| NeuroAccess Platform | Cordance Medical | Pre-clinical/Research |
| Epilepsy Program | Current Surgical | Research |